As the holiday season is upon us, we want to take a moment to wish you all a Merry Christmas and a Happy New Year! This year has been truly remarkable for Nivagen. We are thrilled to share that we achieved a significant milestone — successfully completing an FDA inspection with zero observations (483). Cheers, and we hope to continue growing with your support in 2025! Wishing you a joyful holiday season. ???
关于我们
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world. Our sales and marketing personnel are among the best in the world. The US generic prescription market is currently at approximately $60 billion, and over $120 billion's worth of products will be coming off of patent protection in next 10 years. Nivagen believes that, with its strategic partnership model of global alliances with highly efficient pharmaceutical companies across the globe, we can provide cost savings to the consumer while creating value for all members of the supply chain. Nivagen is focused in three areas of product development: development/co-development, acquisition/in-licensing, and providing sales and marketing services. We are actively looking to partner with CRO and CRAM to co-develop products. We are also acquiring existing products. If you are small FDA qualified manufacturer and want to launch your company or product in the US, Nivagen can provide complete turnkey solutions and cost effective delivery on an accelerated timeline.
- 网站
-
https://www.nivagen.com
Nivagen Pharmaceuticals, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Sacramento,California
- 创立
- 2009
地点
-
主要
3050 Fite Circle
suite 100
US,California,Sacramento,95827
Nivagen Pharmaceuticals, Inc.员工
-
Minal Belani Singh
Fractional GC - Health Law - Community Creator
-
Thomas Henry
Vice President of Sales and Business Development at Nivagen Pharmaceuticals, Inc.
-
Mohammed Taher
Quality Control analyst at Nivagen Pharmaceuticals. Formulation Scientist & Technical Advisor of MFG at BioZone Pharmaceuticals, Inc.
-
Miten Vyasa
Regulatory Affairs/ CMC / US Market / Post Approval RA / Commercial RA / Process Validation, Cleaning Validation & Verification, New Product…
动态
-
This Thanksgiving, we’re filled with gratitude for the trust, collaboration, and support from our incredible community. May your holiday be filled with warmth, love, and cherished memories. Happy Thanksgiving from the Nivagen Team! ???? #HappyHolidays #Thankful
-
-
We are excited to attend the CPHI Milan 2024 ?? October 8th – 10th ?? Fiera Milano, Italy Reach out to [email protected] to schedule a meeting. We look forward to meeting our current and future partners ?? #pharmaceuticals #cphi2024 #milan #nivagen
-
-
Last week, our team had the incredible opportunity to participate in the FDA Compounding Quality Center of Excellence Fifth Annual Conference as panelists, and spectators. Pallavi Devurkar-Badkar , M.S , RPH , BCSCP shared her thoughts: "I was honored to be invited by the FDA to join the panel discussing the challenges of the growing 503B industry. It was a fantastic opportunity to share the stage with other industry leaders in the 503B space." Nirav Patel Ph.D. agreed, noting "The conference provided an invaluable opportunity to network and know more from the peers in the 503B industry." Sachin Arjune , Associate Director of Quality Assurance Senior, also remarked, "It was an incredible experience to learn from industry leaders." We extend our gratitude to the FDA for facilitating this event, which allowed us to gain valuable insights into industry trends and growth opportunities. #FDACompliance #QualityControl #PharmaManufacturing #Nivagen #FDA #FDAAnnual #compoundingquality #conference2024
-
-
?? We are pleased to announce that we have successfully completed the United States Food and Drug Administration (USFDA) Post-marketing Adverse Drug Experience (PADE) Inspection with zero observations. https://rb.gy/riiq4u #usfda #usfda #approvals #drug #insights #pharmashots #pade #usfdaaudits #pharmaceuticals #nivagen